The clearance paves the way for the first preventive flu shot based on mRNA technology and completes a dramatic regulatory ...

The Food and Drug Administration on Wednesday approved the U.S.’s first flu shot that uses mRNA technology: mFlusiva, from ...

Aug 5 (Reuters) - The U.S. Food and Drug Administration has approved Moderna's flu vaccine for people aged 50 and older, the ...

The vaccine could give Moderna a foothold in seasonal flu and strengthen the case for mRNA shots against fast-changing ...

Moderna received FDA approval for its new mRNA-based flu shot for older adults after months of regulatory questioning.

The U.S. Food and Drug Administration has approved Moderna's flu vaccine for people aged 50 and older, the company said on ...

The FDA has approved Moderna's mRNA-based seasonal flu vaccine for adults 50 and older, marking the first such approval in the U.S.

The decision caps a seven-month review that included a rare refusal to consider the shot at all.

The FDA has approved Moderna’s influenza vaccine, the first licensed flu shot made using messenger RNA technology.

Moderna’s mRNA-based flu vaccine, mFlusiva, is approved by the Food and Drug Administration for adults aged 50 and over.

Moderna is known as a coronavirus vaccine giant, but it's progressively becoming a multi-product company. The biotech has several exciting candidates in late-stage trials. 10 stocks we like better ...

The U.S. Food and Drug Administration has approved a new seasonal flu vaccine from Moderna that uses mRNA technology, the ...